PATIENT OR CAREGIVER
Home  |  Privacy Policy  |  Terms and Conditions  |  Contact Medical Information  |  Site Map

Exercise Data in Idiopathic or Heritable Pulmonary Arterial Hypertension (IPAH/HPAH) at 12 Weeks

Increased Exercise Capacity1

Epoprostenol was studied in 2 prospective, open-label, randomized trials of 8 and 12 weeks' duration (pooled data results) in patients with idiopathic pulmonary arterial hypertension (IPAH) or heritable PAH (HPAH). Patients were NYHA Functional Class III or IV, except for 2 patients who were NYHA Functional Class II.

Statistically significant improvement was observed in exercise capacity, as measured by the 6-Minute Walk Test, in patients who received continuous intravenous epoprostenol plus conventional therapy compared to those who received conventional therapy alone. Improvements were apparent as early as the first week of therapy. Conventional therapy could include anticoagulants, oral vasodilators, supplemental oxygen, digoxin, and/or diuretics.

Read about survival data in IPAH/HPAH